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Abstract Imeglimin is a novel agent currently in devel-
opment to treat type 2 diabetes. Laboratory studies have
demonstrated that it has the potential to impact the three
main pathophysiologic components of type 2 diabetes:
impaired glucose uptake by muscle tissue, excess hepatic
gluconeogenesis, and increased beta-cell apoptosis. Pre-
liminary human studies that have been published within the
last 2 years demonstrate that imeglimin improves hemo-
globin A1c and fasting plasma glucose similarly when
compared with metformin and with sitagliptin. There has
also been a low incidence of adverse effects, especially
hypoglycemia, reported in these early human studies.
Currently, imeglimin is lacking long-term evidence to
demonstrate any effects on its cardiovascular safety, and
data on morbidity and mortality, though some studies are
currently in progress. There is great potential for imegli-
min, if FDA approved, to play a significant role in the type
2 diabetes management algorithm.
Key Points
Imeglimin has been shown to have a positive impact
on skeletal muscle glucose uptake, hepatic glucose
production, and beta-cell apoptosis.
Imeglimin has demonstrated similar clinical benefit
in hemoglobin A1c and fasting plasma glucose when
compared with metformin and sitagliptin.
Although imeglimin has not yet achieved FDA
approval, it is a promising new agent that could
impact the treatment of type 2 diabetes.
1 Introduction
Type 2 diabetes (T2DM) is a widespread disease, affecting
more than 380 million people worldwide, with projections
that it will include more than 590 million people across the
planet by 2035 [1]. To address this global concern, sig-
nificant amounts of time, effort and money have been
allocated to treatment, prevention and education by many
entities, including private and public organizations. Despite
best efforts, the prevalence of T2DM continues to rise,
especially considering the increased aging population,
increasing obesity rates and larger numbers of high-risk
ethnic groups [2]. Additionally, the physiologic and pro-
gressive nature of diabetes requires a combination of life-
style modifications and pharmacologic therapy in order to
achieve and maintain long-term glycemic control. The
primary physiologic defects of T2DM include excessive
hepatic glucose production, diminished peripheral glucose
uptake by insulin sensitive tissues and inadequate insulin
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secretion [3]. This article will introduce and review a new
potential pharmacologic agent, imeglimin, comparing its
basic and clinical activity to that of other widely used
medications.
In general, pharmacologic therapy includes not only
initial antihyperglycemic agents, but also more intensive
approaches to glycemic control over time, often requiring
multiple medications with synergistic mechanisms of
action [4]. At first glance it seems that there are sufficient
numbers of therapeutic classes of agents to treat T2DM,
with each class varying in mechanism, safety, efficacy and
route of administration; however, few drugs target all three
of the main defects associated with T2DM, which is why
complex medication regimens are often required to achieve
glycemic control. Metformin is widely recognized as first-
line therapy in multiple treatment algorithms, and is known
to work primarily by limiting hepatic glucose production,
one of the key defects of T2DM [3–5]. Metformin has a
long track record of efficacy, minimal weight gain and low
risk of hypoglycemia. Despite the potential benefits of
metformin, some patients cannot tolerate the gastroin-
testinal (GI) side effects associated with this drug [3].
Insulin secretagogues, such as sulfonylureas and megli-
tinides, are also frequently used early in the treatment of a
patient with diabetes as they generally elicit clinical effi-
cacy in the short term; however, they have been noted to
fail to maintain efficacy over time. While the secretagogues
are targeting one of the component defects of T2DM by
stimulating endogenous insulin secretion, they are often
associated with hypoglycemia and weight gain, thus lim-
iting their use. Thiazolidinediones target a third aspect of
the physiologic defects of the diabetic patient by increasing
insulin sensitivity in the periphery and have shown sus-
tained durability of effect and infrequent incidence of
hypoglycemia; however, they, too, have side effects that
possibly limit their use, such as edema and weight gain [6].
Newer classes of antidiabetic agents that target the
incretin hormones, such as glucagon-like-peptide-1 (GLP-
1) receptor agonists and dipeptidyl-peptidase-IV (DPP-IV)
inhibitors, have recently achieved a presence in the land-
scape of antihyperglycemic drugs. GLP-1 receptor ago-
nists, delivered via subcutaneous injection, promote
glucose-dependent insulin secretion, inhibition of inap-
propriate post-prandial glucagon secretion and slowed
gastric emptying to achieve glycemic control. While they
are not often associated with hypoglycemia and generally
induce some weight loss, the GLP-1 receptor agonists are
often poorly tolerated because of nausea and increased risk
of pancreatitis. Additionally, the FDA has issued a boxed
warning identifying the risk of medullary thyroid cancer
with the GLP-1 receptor agonists [7]. DPP-IV inhibitors
also work on incretin hormones by blocking the enzyme
that is responsible for degrading endogenous GLP-1,
allowing for higher concentrations of GLP-1 to exert its
action; however, it should be noted that glycemic effects
are generally less significant with the DPP-IV inhibitors
compared with the exogenous GLP-1 receptor agonists.
DPP-IV inhibitors, unlike GLP-1 receptor agonists, are
administered orally and generally have good patient tol-
erability and a low incidence of hypoglycemia; however,
the overall efficacy in glucose reduction is minimal com-
pared with other classes [8]. Selective sodium glucose co-
transporter 2 (SGLT-2) inhibitors are the newest agents to
gain approval for the treatment of T2DM. This class has a
unique mechanism of action that does not target the
pathology of diabetes, but works by increasing glucose
excretion in the urine. These agents are not associated with
weight gain or hypoglycemia, but are known to cause an
increase in genital and urinary tract infections for both men
and women [9]. Insulin therapies are by far the most effi-
cacious agents for glycemic control and directly target
insulin deficiency/insufficiency. Insulin does not have dose
limitations or other side effects seen with non-insulin
therapies, but does have a significant risk of hypoglycemia
and weight gain, and patients are generally averse to
starting insulin therapy early on in the course of their
disease [3].
After reviewing these agents used for the treatment of
T2DM, it is evident that no single agent targets the three
primary defects of this widespread disease. Imeglimin is a
drug currently in development as the first in a new class of
oral antidiabetic agents acting on both insulin resistant
organs and well as pancreatic beta cells. Although the
precise mechanism of action has not been fully understood,
it appears, based on pre-clinical results, to target several
components of the pathology of T2DM. In rodent studies, it
has been shown to reduce fasting plasma glucose (FPG),
reduce hemoglobin A1c (A1c) and inhibit hepatic glucose
production similar to metformin. Imeglimin has also been
associated with stimulation of skeletal muscle glucose
uptake, protection against beta-cell apoptosis, and reduc-
tion of liver steatosis. Lastly, imeglimin has been shown to
perform similarly to DPP-IV inhibitors with respect to
glucose-dependent insulin secretion [10]. Researchers hope
this drug will add to the arsenal of existing antidiabetic
agents as either an alternative or complementary option in
any stage of the disease.
2 Laboratory Studies
Imeglimin is a novel agent unlike any other preexisting
therapy for T2DM on the basis of its structure and pro-
posed mechanism of action. Imeglimin is the first in the
class of drugs called the ‘‘glimins’’ and, more specifically,
is a tetrahydrotriazene compound [11]. Animal studies,
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primarily in rodent models, have been previously published
describing the effects of imeglimin on three primary
pathophysiologic defects associated with T2DM.
One such target defect of T2DM is excessive hepatic
glucose production, and has been evaluated in rat hepato-
cytes with chemically induced T2DM [11]. Hepatocytes
that were exposed to imeglimin versus placebo demon-
strated a statistically significant decrease (p\ 0.01) in the
level of gluconeogenesis activity. This effect on hepatic
glucose production appeared to be dosage dependent, with
the highest imeglimin concentrations eliciting inhibitory
activity similar to the level of efficacy of metformin, as
seen in previous trials.
The second physiologic target of imeglimin is skeletal
muscle glucose uptake, which has been evaluated with both
in vitro and in vivo studies in rodents. In vitro studies
involving isolated mouse tissue cells demonstrated a sta-
tistically significant and dose-dependent improvement
(p\ 0.001) in glucose uptake when exposed to imeglimin
and glucose in their growth medium [11]. In in vivo
studies, rats with chemically induced T2DM were admin-
istered oral doses of imeglimin and monitored for a 45-day
treatment period. When radioactive glucose was adminis-
tered to the rats, skeletal muscle uptake of these glucose
molecules were monitored and recorded. Glucose uptake
with all doses of imeglimin was significantly higher
(p\ 0.01) compared with controls even at the lowest dose.
The protective effect of imeglimin against beta-cell
apoptosis was also tested in rats, and its effects were
compared with those of exenatide, an agent known to have
beta-cell protection. Isolated rat islet cells were incubated
in either imeglimin or exenatide and then exposed to toxic
cytokines, and the proportion of cell death was measured
and compared [11]. Although no statistical significance
was reported, 37 % less cell apoptosis occurred in islet
cells incubated in imeglimin versus 29 % less cell death
with exenatide exposure. These results are comparable,
suggesting that imeglimin does provide some protective
effects towards the beta cells of rat pancreas tissue.
Most promisingly, rat subjects with either chemically or
genetically induced T2DM showed dose-dependent
improvements in A1c, glucose tolerance and FPG that were
comparable with metformin after a 35-day treatment with
oral forms of each drug [11]. These results further support
the theory that imeglimin provides similar benefit in mul-
tifaceted ways when compared with the existing treatment
modalities for T2DM.
Lastly, a study of rodents fed high-fat, high-sucrose
diets who received 6 weeks of imeglimin therapy also
indicated significant reduction of glycemia, restoration of
normal glucose tolerance, improved insulin sensitivity in
liver and skeletal muscle as well as reduction of liver
steatosis [12]. Unlike previous studies, however, Vial et al.
[12] found that these larger effects are likely produced by
improvement in hepatic mitochondrial functioning. Vial
proposed that imeglimin induces an increase in mitochon-
drial phospholipid composition which decreases the pro-
duction of reactive oxygen species and contributes to
improved functioning.
Moving forward from animal studies, four human trials
have recently been published that demonstrate how ime-
glimin fares as monotherapy as well as adjunctive therapy
with metformin or sitagliptin.
3 Clinical Studies
With respect to human studies, data are somewhat limited
as imeglimin is still in clinical trials. Pacini et al. [13]
completed a study to explore whether beta-cell function
could contribute to the mechanism of action of imeglimin.
In a double-blind, randomized, placebo-controlled study of
33 patients with T2DM (A1c 6.8 ± 0.1 %) who were
either treatment naı¨ve (n = 4) or had only been managed
with metformin (n = 29), 7 days of imeglimin treatment
significantly raised the insulin secretory response (ISR) to
glucose by 112 % (p = 0.035), first-phase ISR by ?110 %
(p = 0.034) and second-phase ISR by ?29 % (p = 0.031)
[13]. Imeglimin also improved beta-cell glucose sensitivity
by 36 % (p = 0.034). The authors felt that these results
were similar to preclinical studies and indicate direct
effects on beta-cell function, and the mechanisms at this
level require elucidation.
Pirags et al. conducted two phase II studies with dif-
ferent durations to (1) unravel the best drug regimen
between once daily versus twice daily administration and
(2) demonstrate the potential range of the active dose of
imeglimin. The 4-week study was a randomized, double-
blind, double-dummy, three-arm parallel-group, multiple-
dose study performed in Germany [11]. Fifty-nine subjects
that were treatment naı¨ve or treated with either metformin
or sulfonylurea were randomized to study doses of ime-
glimin 2000 mg every evening, imeglimin 1000 mg twice
daily, or metformin 850 mg twice daily. The 4-week study
demonstrated that the most notable decrease in area under
the curve (AUC) plasma glucose after an oral glucose
tolerance test was with imeglimin twice daily
(p\ 0.0001), followed by metformin (p\ 0.0004) [14].
There was no significant difference between the metformin
and imeglimin twice daily group (p = 0.8321). First-phase
insulin secretion, AUC0–30 min insulin/AUC0–30 min glucose
increased with both imeglimin twice daily by 72 % and
metformin by 38 % compared with baseline.
The second study by Pirags et al. was performed over
8 weeks as a randomized, double-blind, four-arm, con-
trolled, multi-center study performed at seven sites in
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Latvia [11]. One hundred twenty-eight patients were ran-
domized to imeglimin 500 mg twice daily, imeglimin
1500 mg twice daily, metformin 850 mg twice daily, or
placebo. This study demonstrated that imeglimin 1500 mg
twice daily, but not imeglimin 500 mg twice daily, was
significantly superior to placebo in reducing plasma glu-
cose AUC0–6 h, but not significantly different when com-
pared with metformin. Although not statistically
significant, FPG decreased in both imeglimin 1500 mg
twice daily and metformin 850 mg twice daily groups from
baseline values, 172.26 and 169.38 to 154.26 and
144.72 mg/dl, respectively [14]. The ratio of AUC insulin/
AUC glucose increased during the study in both imeglimin
and metformin treatment groups compared with placebo,
indicating an increase in insulin secretion.
In both studies, although the incidence of adverse events
was quite different, imeglimin was generally well tolerated,
with the most frequent adverse effects being headache and
GI-related side effects, some of which include nausea,
vomiting, and diarrhea. No serious or severe adverse
effects, including echocardiographic and vital signs chan-
ges, were noted with imeglimin [14].
In a 12-week multi-center, randomized, placebo-con-
trolled, parallel study conducted by Fouqueray et al., 156
patients were randomized 1:1 to receive imeglimin
1500 mg twice daily or placebo in addition to a lead-in dose
of metformin [14]. The mean metformin dose of approxi-
mately 1900 mg/day remained the same throughout the
study for both treatment arms. By the completion of the
study, A1c decreased by 0.65 % in the imeglimin group and
by 0.21 % in the placebo group (p = 0.001) from a baseline
A1c of 8.5 and 8.6 % in the imeglimin and placebo arms,
respectively [14]. Additionally, there were statistically
significant reductions in FPG (p\ 0.001) and the proin-
sulin/insulin ratio (p = 0.007) from baseline compared with
placebo. Greater than 60 % of patients in the imeglimin
group achieved a decrease in A1c ofC0.5 % compared with
36.4 % in the placebo group. Around 14 % of subjects
receiving imeglimin achieved an A1c of\7 % compared
with only 3.8 % of participants in the placebo group.
Overall, imeglimin was well tolerated without any
serious cardiovascular events or adverse events. Of note,
there were no statistically significant changes in mean body
weight (p = 0.08) and waist circumference (p = 0.053) in
the imeglimin versus placebo group [14]. This study
demonstrated that in combination with metformin, there
were clinically and statistically significant reductions in the
A1c, FPG, and proinsulin/insulin ratio. Additionally, this
novel drug in a class of its own can be offered as an add-on
therapy with metformin as a potential alternative to other
second-line agents.
Fouqueray et al. also assessed the safety and efficacy of
add-on imeglimin therapy in patients inadequately
controlled on sitagliptin monotherapy in a 12-week,
29-center, three-country, randomized, double-blind, pla-
cebo-controlled, parallel study of 170 subjects with T2DM
[15]. The researchers conducted a 12-week run-in period in
which all subjects were converted from current therapy
(10 % were treatment naı¨ve vs. a 90 % majority on met-
formin therapy) to sitagliptin 100 mg/day for 10 weeks,
followed by 2 weeks of sitagliptin and placebo. Baseline
labs were drawn at the end of this 12-week run-in period,
and patients were then randomized to receive sitagliptin
100 mg/day plus imeglimin 1500 mg twice daily or pla-
cebo. Monitoring was carried out at baseline and at weeks 4,
8 and 12. There was a statistically significant difference in
change in A1c from baseline (baseline A1c of 8.5 %) in the
sitagliptin ? imeglimin group (-0.6 %) compared with the
sitagliptin ? placebo group (?0.12 %) (-0.72 % differ-
ence; p\ 0.001) and in FPG (-16.75 mg/dl vs. -1.98 mg/
dl; -14.77 mg/dl difference; p = 0.014). Larger reductions
in A1c were seen in patients with higher baseline A1c (-
0.9 % with baseline A1c of[9 %). There was no significant
difference between the groups with regard to beta-cell
function parameters, as was expected: insulin (uIU/ml),
c-peptide (ng/ml), proinsulin/insulin ratio and/or homeo-
static model assessment of insulin resistance. No significant
differences from baseline to week 12 between groups were
identified with respect to triglycerides, C-reactive protein or
systolic blood pressure. Weight and waist circumference
were not impacted in the combination group compared with
sitagliptin alone as seen in prior studies (reduced parame-
ters) [11]. There were no reported hypoglycemic events
reported in the combination group. Additionally, there were
fewer adverse events in the imeglimin group versus the
placebo group [seven events in three subjects (one requiring
rescue therapy) in placebo vs. none in the imeglimin group]
[15]. As in the previously mentioned study with metformin,
this study demonstrated that imeglimin is well tolerated and
efficacious in reducing A1c when added to sitagliptin
monotherapy, making it a potential complement to either
metformin or sitagliptin for the treatment of T2DM. See
Table 1 for a summary of study evidence.
4 Discussion and Conclusions
Despite all of the promising preliminary information
currently available, further evidence is needed to support
the long-term safety of imeglimin and ultimately result in
its FDA approval. Currently, there is one known study
involving imeglimin that has been completed, but its
results are yet to be published. This study is a random-
ized, prospective, placebo-controlled trial based in Latvia
that intends to assess both efficacy and safety endpoints
with 24 weeks of imeglimin treatment [16]. Patients
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included in this trial may be either treatment naı¨ve or
have been previously treated with oral monotherapy.
Trials assessing the safety and efficacy of imeglimin with
insulin therapy or compared directly with insulin are yet
to be published.
Ultimately, the place that imeglimin will have in the
current T2DM treatment algorithm is unknown. At this
time, there are no available data that investigate the impact
of imeglimin on morbidity and/or mortality in patients with
T2DM. More data that support the long-term safety of
imeglimin are necessary as well. However, based on the
results of the animal studies and human trials that have
been published recently, imeglimin seems to be a promis-
ing adjunct, or even a potential initial monotherapy agent,
in treating T2DM.
Acknowledgments The authors would like to acknowledge each
other in the preparation and review of this manuscript.
Compliance with Ethical Standards
Funding No funding was received for the preparation of this
manuscript.
Conflicts of interest The authors, Valerie Vuylsteke, Lisa M.
Chastain, Geeta A. Maggu and Crystal Brown, disclose that they have
no conflicts of interest regarding the outcomes of the research pre-
sented and reviewed in this manuscript.
Open Access This article is distributed under the terms of the
Creative Commons Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/by-nc/4.0/), which
permits any noncommercial use, distribution, and reproduction in any
medium, provided you give appropriate credit to the original
author(s) and the source, provide a link to the Creative Commons
license, and indicate if changes were made.
References
1. International Diabetes Foundation. Diabetes: facts and figures.
Available from: http://www.idf.org/worlddiabetesday/toolkit/gp/
facts-figures. Cited 16 Nov 2013.
2. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of
NIDDM. A balanced overview. Diabetes Care. 1992;15:318–68.
3. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of
hyperglycemia in type 2 diabetes: a patient-centered approach:
position statement of the American Diabetes Association (ADA)
and the European Association for the Study of Diabetes (EASD).
Diabetes Care. 2012;35(6):1334–79.
4. Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE compre-
hensive diabetes management algorithm 2013 consensus state-
ment. Endocr Pract. 2013;19(Suppl 2):1–48.
5. Qaseem A, Humphrey L, Sweet D, et al. Oral pharmacologic
treatment of type 2 diabetes mellitus: a clinical practice guideline
from the American College of Physicians. Ann Intern Med.
2012;156:218–31.
6. Actos [package insert]. Deerfield: Takeda Pharmaceutical; 2013.
7. Byetta [package insert]. San Diego: Amylin Pharmaceutical;
2011.
8. Januvia [package insert]. Whitehouse Station: Merck & Co; 2014.
9. Farxiga [package insert]. Princeton: Bristol-Myers Squibb; 2014.
10. Fouqueray P, Leverve X, Fontaine E, et al. Imeglimin—a new
oral anti-diabetic that targets the three key defects of type 2
diabetes. J Diabetes Metab. 2011;2:126.
11. Pirags V, Lebovitz H, Fouqueray P. Imeglimin, a novel oral
antidiabetic, exhibits a good efficacy and safety profile in type 2
diabetic patients. Diabetes Obes Metab. 2012;14:852–8.
Table 1 Summary of clinical study evidence
References Imeglimin dose Comparator Results P value
Fouqueray
et al. [15]
1500 mg BID ?
sitagliptin
Placebo ? sitagliptin Change in A1c from baseline at 12 weeks (-0.6 vs. ?0.12 %) \0.001





1500 mg BID ?
metformin
Placebo ? metformin Change in A1c from baseline at 12 weeks (-0.65 vs. -0.21 %) \0.001
Change in FPG from baseline at 12 weeks (-0.91 mg/dl
vs. ?0.36 mg/dl)
\0.001





2000 mg once daily Metformin 850 mg
twice daily
Change in baseline of AUC plasma glucose at 4 weeks
(-10 vs. 30 %)
\0.0001,
\0.0004
1000 mg twice daily Change in baseline of AUC plasma glucose at 4 weeks
(-33 vs. 30 %)
\0.0305,
\0.0004
500 mg twice daily Metformin 850 mg
twice daily or
placebo
AUC glucose at week 8 (72,661 vs. 58,054 or 78,174 mg/dl) Not
providedFPG at week 8 (172 vs. 144.7 or 182 mg/dl)
A1c at week 8 (7.58 vs. 6.97 or 7.52 %)
1500 mg twice daily AUC glucose at week 8 (63,293 vs. 58,054 or 78,174 mg/dl)
FPG at week 8 (154 vs. 144.7 or 182 mg/dl)
A1c at week 8 (7.17 vs. 6.97 or 7.52 %)
AUC area under the curve, A1c hemoglobin A1c, BID twice a day, FPG fasting plasma glucose
Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes 231
12. Vial G, Chauvin MA, Bendridi N, Durand A, Meugnier E, Madec
AM, Bernoud-Hubac N, Pais de Barros JP, Fontaine E´, Acqua-
viva C, Hallakou-Bozec S, Bolze S, Vidal H, Rieusset J. Ime-
glimin normalizes glucose tolerance and insulin sensitivity and
improves mitochondrial function in liver of a high-fat, high-su-
crose diet mice model. Diabetes. 2015;64(6):2254–64.
13. Pacini G, Mari A, Fouqueray P, Bolze S, Roden M. Imeglimin
increases glucose-dependent insulin secretion and improves beta-
cell function in patients with type 2 diabetes. Diabetes Obes
Metab. 2015;17:541–5.
14. Fouqueray P, Pirags V, Inzucchi SE, Bailey CJ, Schernthaner G,
Diamant M, et al. The efficacy and safety of imeglimin as add-on
therapy in patients with type 2 diabetes inadequately controlled
with metformin monotherapy. Diabetes Care. 2013;36(3):565–8.
15. Fouqueray P, Pirags V, Diamant M, Schernthaner G, Lebovitz
HE, Inzucchi SE, et al. The efficacy and safety of imeglimin as
add-on therapy in patients with type 2 diabetes inadequately
controlled with sitagliptin monotherapy. Diabetes Care.
2014;37(7):1924–30.
16. A study of the efficacy and safety of 4 doses of imeglimin after
24 weeks of treatment in subjects with type 2 diabetes. http://
www.clinicaltrials.gov. Accessed 1 Jun 2015.
232 V. Vuylsteke et al.
